| An inhibitor of oxidative phosphorylation exploits cancer vulnerability JR Molina, Y Sun, M Protopopova, S Gera, M Bandi, C Bristow, T McAfoos, ... Nature medicine 24 (7), 1036-1046, 2018 | 717 | 2018 |
| Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia R Pan, LJ Hogdal, JM Benito, D Bucci, L Han, G Borthakur, J Cortes, ... Cancer discovery 4 (3), 362-375, 2014 | 717 | 2014 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 349 | 2021 |
| Repression of BMI1 in normal and leukemic human CD34+ cells impairs self-renewal and induces apoptosis A Rizo, S Olthof, L Han, E Vellenga, G De Haan, JJ Schuringa Blood, The Journal of the American Society of Hematology 114 (8), 1498-1505, 2009 | 172 | 2009 |
| Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models L Han, Q Zhang, M Dail, C Shi, A Cavazos, VR Ruvolo, Y Zhao, E Kim, ... Haematologica 105 (3), 697, 2020 | 98 | 2020 |
| Single‐cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3‐ITD‐mutated AML stem/progenitor cells L Han, P Qiu, Z Zeng, JL Jorgensen, DH Mak, JK Burks, W Schober, ... Cytometry Part A 87 (4), 346-356, 2015 | 98 | 2015 |
| Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, ... Signal transduction and targeted therapy 7 (1), 51, 2022 | 70 | 2022 |
| SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome H Alachkar, R Santhanam, K Maharry, KH Metzeler, X Huang, ... The Journal of clinical investigation 124 (4), 1512-1524, 2014 | 66 | 2014 |
| Oral MEK 1/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: a phase II study BK Ragon, O Odenike, MR Baer, W Stock, G Borthakur, K Patel, L Han, ... Clinical Lymphoma Myeloma and Leukemia 19 (7), 431-440. e13, 2019 | 62 | 2019 |
| Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014; 4: 362–375. doi: 10.1158/2159-8290 R Pan, LJ Hogdal, JM Benito, D Bucci, L Han, G Borthakur, J Cortes, ... CD-13-0609.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 62 | |
| Long‐term efficacy and safety of arsenic trioxide for first‐line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia Y Zhang, Z Zhang, J Li, L Li, X Han, L Han, L Hu, S Wang, Y Zhao, X Li, ... Cancer 119 (1), 115-125, 2013 | 56 | 2013 |
| Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell … Q Zhang, C Shi, L Han, N Jain, KG Roberts, H Ma, T Cai, A Cavazos, ... Oncotarget 9 (8), 8027, 2018 | 48 | 2018 |
| Antileukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody conjugate, in acute myeloid leukemia L Han, JL Jorgensen, C Brooks, C Shi, Q Zhang, GM Nogueras González, ... Clinical Cancer Research 23 (13), 3385-3395, 2017 | 45 | 2017 |
| Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses L Han, ATJ Wierenga, M Rozenveld-Geugien, K van de Lande, ... PLoS One 4 (11), e7989, 2009 | 42 | 2009 |
| 2021 update measurable residual disease in acute myeloid leukemia: European leukemia net working party consensus document M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood 138 (26), 2753-2767, 2021 | 36 | 2021 |
| Initial report of a phase I study of LY2510924, idarubicin, and cytarabine in relapsed/refractory acute myeloid leukemia P Boddu, G Borthakur, M Koneru, X Huang, K Naqvi, W Wierda, P Bose, ... Frontiers in Oncology 8, 369, 2018 | 31 | 2018 |
| KRASG12V enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways S Fatrai, D Van Gosliga, L Han, SMGJ Daenen, E Vellenga, JJ Schuringa Journal of biological chemistry 286 (8), 6061-6070, 2011 | 31 | 2011 |
| Ruxolitinib or dasatinib in combination with chemotherapy for patients with relapsed/refractory Philadelphia (Ph)-like acute lymphoblastic leukemia: a phase I-II trial N Jain, EJ Jabbour, PZ McKay, F Ravandi, K Takahashi, T Kadia, ... Blood 130, 1322, 2017 | 29 | 2017 |
| Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia L Zhang, T Cai, X Lin, X Huang, MH Bui, JP Plotnik, RJ Bellin, EJ Faivre, ... Molecular cancer therapeutics 20 (10), 1809-1819, 2021 | 23 | 2021 |
| Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells T Cai, A Gouble, KL Black, A Skwarska, AS Naqvi, D Taylor, M Zhao, ... Nature communications 13 (1), 2228, 2022 | 21 | 2022 |
